UsHERing in New Standards of Care on HER2+ and HER2-Low MBC

Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.

Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.

Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.

Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.

Join us as expert faculty, Dr. Adam Brufsky and Dr. Christopher Gallagher, discuss the qualities of credible real world evidence (RWE) publications, application of CDK4/6 inhibitor RWE in hormone receptor positive metastatic breast cancer, and integrating RWE into everyday clinical decision and shared decision making conversations. This 15-minute activity provides a practical discussion to increase clinician familiarity and comfort with RWE of CDK4/6 inhibitors in metastatic breast cancer and clinicians’ confidence in their ability to discuss RWE with their patients.

This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.

This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.

This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.

This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.

This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.